通用名称

tacrolimus

儿科标签批准日期

2018/11/29 0:00:00

特定指示/秒

Prophylaxis of organ rejection in kidney transplant patients, in combination with other immunosuppressants.

标签更改摘要

- Safety and effectiveness of Astagraf XL in de novo pediatric kidney transplant patients have been established. - Use in pediatric kidney transplant patients is based on adequate and well controlled studies of Astagraf XL in adult kidney transplant patients and supported by pharmacokinetic and safety data in pediatric transplant patients 4 years of age and older who are able to swallow capsules intact and Prograf (tacrolimus) capsules in adult and pediatric transplant patients. - A pharmacokinetic and safety study included 25 de novo pediatric kidney transplant patients, 4 to 15 years of age, randomized and treated with either Prograf (n=12) or Astagraf XL (n=13). - Another pharmacokinetic and safety study included 48 stable pediatric kidney transplant patients, 5 to 16 years of age, who were converted from a Prograf-based regimen to Astagraf XL. - Information on dosing, clinical trials, adverse reactions and PK parameters. - Postmarketing study

治疗类别

Immunologic agent

立法类型

PREA Only

产品说明书链接